# Clec7a-targeted Res@GelMA hydrogels regulate macrophage polarization to reduce neuroinflammation and promote spinal cord repair

**Authors:** Zhonglian Zhu, Jiankang Chang, Xubin Gao, Zhaodong Wang, Keyou Duan, Jianzhong Guan

PMC · DOI: 10.1186/s13018-025-06631-0 · Journal of Orthopaedic Surgery and Research · 2026-01-24

## TL;DR

A new hydrogel material reduces spinal cord inflammation and promotes healing by regulating immune cells.

## Contribution

A Res@GelMA hydrogel was developed to target macrophage polarization and reduce neuroinflammation after spinal cord injury.

## Key findings

- Res@GelMA promotes M2 macrophage polarization and reduces inflammatory factors like IL-1β, IL-6, and TNF-α.
- Clec7a was identified as a key target gene regulated by Res@GelMA, which inhibits the TLR2/TLR4-p38 MAPK signaling pathway.
- In a mouse model, Res@GelMA improved tissue repair and motor recovery after spinal cord injury.

## Abstract

Excessive inflammation driven by macrophage phenotype imbalance is a key pathological barrier hindering neural repair after spinal cord injury (SCI). Here, methacryloyl gelatin hydrogel (GelMA) loaded with natural anti-inflammatory agent resveratrol (Res) was designed and synthesized. Scanning electron microscopy (SEM), x-ray diffraction (XRD), fourier-transform infrared spectroscopy (FT-IR), Ultraviolet (UV) and rheological characterization confirmed that Res-loaded GelMA hydrogel (Res@GelMA) was successfully synthesized. High-Performance Liquid Chromatography (HPLC) analysis demonstrated sustained Res release. CCK8 and cell adhesion experiments confirmed that Res@GelMA treatment did not affect the cell function of RAW264.7 and had good cell compatibility. Flow cytometry, Enzyme-Linked Immunosorbent Assay (ELISA) and western blot assays revealed that Res@GelMA treatment promoted RAW264.7 to M2 polarization, while reducing the levels of inflammatory factors (IL-1β, IL-6, TNF-α) and down-regulating the expression of IL-1R1/MyD88/TNFR1 inflammatory signaling proteins. Transcriptome sequencing combined with functional screening identified C-type lectin receptor Clec7a as a key target gene regulated by Res@GelMA. Importantly, knockdown of Clec7a and Res@GelMA were both anti-inflammatory, promoted M2 polarization, and blocked the activation of the TLR2/TLR4-p38 MAPK signaling axis. In the SCI mouse model, local implantation of Res@GelMA significantly improved tissue pathological damage and enhanced motor function recovery compared with free Res or blank GelMA. In addition, Res@GelMA achieved systemic anti-inflammation by downregulating the Clec7a-TLR-p38 pathway in the injured area and promoting M2 polarization. This study developed an anti-inflammatory hydrogel material that can regulate the phenotype of macrophages, laying a theoretical and technical foundation for the development of neural repair strategies targeting the inflammatory microenvironment.

The online version contains supplementary material available at 10.1186/s13018-025-06631-0.

## Linked entities

- **Genes:** CLEC7A (C-type lectin domain containing 7A) [NCBI Gene 64581], IL1R1 (interleukin 1 receptor type 1) [NCBI Gene 3554], MYD88 (MYD88 innate immune signal transduction adaptor) [NCBI Gene 4615], TNFRSF1A (TNF receptor superfamily member 1A) [NCBI Gene 7132], TLR2 (toll like receptor 2) [NCBI Gene 7097], TLR4 (toll like receptor 4) [NCBI Gene 7099], P38mapk (p38 map kinase) [NCBI Gene 692545]
- **Chemicals:** resveratrol (PubChem CID 5056)
- **Diseases:** spinal cord injury (MONDO:0043797)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Il1b (interleukin 1 beta) [NCBI Gene 16176] {aka IL-1beta, Il-1b}, Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, Tlr4 (toll-like receptor 4) [NCBI Gene 21898] {aka Lps, Ly87, Ran/M1, Rasl2-8}, Tlr2 (toll-like receptor 2) [NCBI Gene 24088] {aka Ly105}, Il6 (interleukin 6) [NCBI Gene 16193] {aka Il-6}, Mapk14 (mitogen-activated protein kinase 14) [NCBI Gene 26416] {aka CSBP2, Crk1, Csbp1, Mxi2, PRKM14, PRKM15}, Clec7a (C-type lectin domain family 7, member a) [NCBI Gene 56644] {aka BGR, Clecsf12, beta-GR}, Myd88 (myeloid differentiation primary response gene 88) [NCBI Gene 17874], Il1r1 (interleukin 1 receptor, type I) [NCBI Gene 16177] {aka CD121a, CD121b, IL-1R-1, IL-1R-alpha, IL-1R1, IL-1RT-1}, Tnfrsf1b (tumor necrosis factor receptor superfamily, member 1b) [NCBI Gene 21938] {aka CD120b, TNF-R-II, TNF-R2, TNF-R75, TNF-alphaR2, TNFBR}
- **Diseases:** inflammation (MESH:D007249), SCI (MESH:D013119), neuroinflammation (MESH:D000090862)
- **Chemicals:** Res (MESH:D000077185), GelMA (-)
- **Species:** Mus musculus (house mouse, species) [taxon 10090]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12911380/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12911380/full.md

---
Source: https://tomesphere.com/paper/PMC12911380